Government Filing Targets Hospital Markups on Medicines and Consumables
The government has told the Supreme Court that hospitals charging patients high MRPs for medicines and consumables amounts to malpractice, placing the issue squarely in the courtroom and the health policy arena. The affidavit describes a system in which patients face steep price markups despite India’s large and highly competitive drug manufacturing base, where many medicines are produced at comparatively low cost but sold to patients at far higher rates inside hospital systems.
The filing goes beyond a routine pricing complaint. It frames the problem as a structural imbalance in hospital purchasing and billing, where patients arrive with urgent clinical need but very little negotiating power, limited information about substitutes, and little ability to challenge what is added to the final bill. In practical terms, that makes the point of care into a point of vulnerability.
Hospitals are not being accused here of a minor pricing discrepancy. The affidavit describes a market failure with direct bedside consequences.
Low Bargaining Power Meets High-Margin Hospital Billing
The central argument in the filing is simple: health care is not a normal retail transaction. Patients do not compare prices in real time when they need chemotherapy, surgery, or inpatient treatment, and they rarely know which brand or formulation is being dispensed. That information gap gives hospitals and linked pharmacies enormous leverage over the final price of drugs and consumables.
The affidavit says the Indian drug market is highly competitive, with many companies in each drug segment and some of the lowest prices in the world. Under ordinary market conditions, strong competition should restrain prices. In hospital care, however, the patient is not buying on an open shelf in a free market. The hospital often controls procurement, dispensing, and billing at the same time, so the patient sees the bill only after the clinical decision has already been made.
In that setting, trade margins can widen dramatically. The filing says hospitals buy medicines from manufacturers who offer the highest trade margin and then sell those medicines to patients at MRP, with margins ranging from 170% to 700% or more in the case of anti-cancer drugs. Consumables can carry even steeper markups, with margins of 100% to 1000% or more described in the affidavit. For a patient already facing a serious illness, those figures can translate into sudden and severe out-of-pocket spending.
Cancer Drugs and Consumables Draw the Sharpest Concern
Anti-cancer drugs occupy a particularly sensitive place in this dispute because they are often long-course therapies, used repeatedly, and tied to life-altering diagnoses. Large markups on oncology medications do not merely inflate a pharmacy bill; they can alter adherence, delay treatment initiation, or force families to choose between clinical care and financial survival. When a hospital charges a steep premium on a cancer medicine, the cost shock arrives at a moment when the patient is least able to bargain and most dependent on timely treatment.
Consumables add another layer of concern. The affidavit says hospitals commonly purchase items with high MRPs and high margins but low distributor prices, then bill them separately for patients paying directly rather than through government schemes or insurance. Under package-based reimbursement, hospitals and payers negotiate fixed rates for major procedures and disease packages, which helps flatten these spikes. Direct payers often do not get that protection, leaving them exposed to itemized charges that can escalate quickly during admission.
The difference between a package and a line item is not abstract. It determines whether a family faces a predictable bill or a rolling cascade of add-ons.
Ceiling Prices and Policy Intervention Already Under Way
The filing also lays out measures already taken to rein in medicine pricing. Government has fixed ceiling prices for 935 scheduled formulations and retail prices for 3,881 new drugs. Those figures matter because they show the issue is not being raised for the first time; rather, the affidavit places hospitals within a broader regulatory effort to control costs across the medicine supply chain.
The petition before the court was filed by Dr Sanjay Kulshrestha and refers to a Niti Aayog report as well as a 2020 statement by then health minister Harsh Vardhan, who said health spending pushed an estimated six crore families below the poverty line each year. That context gives the dispute a blunt public-health dimension: drug pricing is not only a matter of market efficiency, but of catastrophic household expenditure and preventable impoverishment.
For regulators, the challenge is not just whether medicines are cheap at the factory gate. The harder problem is how quickly price multiplies once the drug enters the hospital ecosystem. Procurement decisions, trade incentives, pharmacy ownership, and billing practices can all push the final figure far beyond the manufacturing cost.
What the Case Reveals About Hospital Finance and Patient Risk
This case exposes a familiar fault line in hospital care: clinical dependence creates financial dependence. Patients trust the institution to provide treatment, but that same institution may control the supply chain, the pharmacy, and the invoice. In a system with weak price transparency, the person needing care has little room to question a prescription substitute, a branded consumable, or a sudden increase in the bill.
That dynamic is especially consequential in inpatient care, where the urgency of illness collapses normal consumer choice. A patient admitted for cancer treatment, surgery, or another major procedure is unlikely to compare distributors or verify trade margins while trying to recover. The result is a setting ripe for overbilling unless pricing rules, disclosure requirements, and procurement oversight are enforced with real discipline.
The affidavit does not present a final resolution. It does, however, place the burden of explanation on hospitals and the pricing system around them, while signaling that government is reviewing interventions in consultation with stakeholders. The immediate unresolved question is how any curb on pricing will be applied inside hospital networks where procurement, dispensing, and billing are tightly linked. Until that is answered, patients making direct payments remain the group most exposed to hospital markups.